ArticleBMC nephrology2026
Sulfadiazine-induced crystalline nephropathy: a case report of a reversible cause of acute kidney injury in advanced HIV.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCrystal-induced acute kidney injury (AKI) is caused by the intratubular precipitation of crystals, which results in obstruction. Crystal-induced AKI mostly occurs as a result of acute uric acid nephropathy and following the administration of drugs or toxins that are poorly soluble. CASE DESCRIPTION: A 23-year-old man presented with AIDS and 1 week history of right sided weakness. Brain MRI showed bilateral ring enhancing lesions. Patient was empirically started on pyrimethamine, sulfadiazine and leucovorin. Brain biopsy confirmed the diagnosis of toxoplasmosis. Hospital course was complicated by AKI and labs showed serum creatinine 2.0 mg/dL (baseline 0.8 mg/dL). Urinalysis showed no hematuria or pyuria with urine pH of 6. Examination of urine sediments under polarized light revealed multiple yellow brown asymmetric rosette shaped crystals (sulfonamide crystals). Sulfadiazine was discontinued and patient was switched to clindamycin. Patient was treated with IV fluids (sodium bicarbonate) for urinary alkalinization. The patient’s serum creatinine returned to baseline within 8 days. DISCUSSION: Sulfadiazine induced crystalluria is a serious complication in patients with AIDS who are treated for toxoplasmosis. Predisposing factors include high dose of sulfadiazine and volume depletion. It usually presents with AKI within 3 weeks of starting the medication. Treatment requires stopping the offending agent, aggressive IV hydration (urine output at least 1.5 L/day) and bicarbonate infusion for urinary alkalinization (goal pH > 7).
conclusionThis case highlights sulfadiazine-induced crystal nephropathy as a reversible cause of AKI. Early drug withdrawal, aggressive hydration, and urinary alkalinization are crucial for recovery. Preventive measures, especially hydration and urine pH monitoring, can significantly reduce risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.